Navigation Links
Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
Date:5/14/2008

SUNNYVALE, Calif., May 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has filed a Schedule 14D-9 Solicitation/Recommendation Statement with the Securities and Exchange Commission (the "Commission"), as required by the Commission's rules, in response to an unsolicited tender offer (the "Offer") by RWD Acquisition I LLC (the "Purchaser") to purchase up to 4 million shares of the common stock of Pharmacyclics, Inc. (the "Company") for $1.05 per share. The terms and conditions of the Offer are set forth in an Offer to Purchase and the related Letter of Transmittal (collectively, the "Offer to Purchase") filed with the Commission by the Purchaser on May 1, 2008. Robert W. Duggan, one of the Company's principal stockholders and a member of the Company's board of directors (the "Board") is the sole member of Purchaser.

The Board is expressing no opinion to the Company's stockholders and is remaining neutral with respect to the Offer. The Board has not made a determination whether the Offer is fair to or in the best interests of the Company's stockholders and is not making a recommendation regarding whether the Company's stockholders should accept the Offer and tender their Shares, and if so how many shares to tender, or reject the Offer and not tender their Shares. The Company believes that a stockholder's decision on whether or not to tender shares in the Offer and, if so, how many shares to tender, is a personal investment decision based upon each individual stockholder's particular circumstances. The Company believes that each stockholder should review the Offer, consult with such holder's financial, tax and accounting advisors and make an independent determination.

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities of Pharmacyclics, Inc. Stockholders are advised to make their own decisions on whether to tender their shares and accept the Offer, based on all of the available information, including the factors considered by the Board. These factors are described in the Company's Schedule 14D-9, filed today with the Commission. The Schedule 14D-9 and the Offer to Purchase contain important information that should be read carefully before any decision is made with respect to the Offer. Stockholders can receive copies of such documents free of charge at the SEC's web site, http://www.sec.gov. The Purchaser has stated that copies of the Offer to Purchase will be made available at Purchaser's expense. Stockholders who wish to receive copies of the Offer to Purchase should contact MacKenzie Partners, Inc., the information agent for the Offer, collect at (212) 929-5500 or toll- free at (800) 322-2885. Stockholders may also obtain free copies of the Company's Schedule 14D-9 and other documents filed with the Commission by contacting Leiv Lea, Vice President, Finance and Administration and Chief Financial Officer and Secretary, in writing at 995 East Arques Avenue, Sunnyvale, California 94085 or by telephone at (408) 774-0330.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmacyclics Reports Third Quarter 2008 Financial Results
2. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
3. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
4. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
5. Castle Connollys Long Islands Top Doctors Published in Newsday Generates More Than 1.1 Million Views of Top Doctors Profiles in Single Day
6. The Quantum Group Files Four Additional Patents
7. Phyhealth Files Historical Financials With the Pink Sheets and Takes Next Step Toward Becoming Fully Reporting
8. Laser Energetics Files Patent Application for a New BrightStar(TM) Alexandrite Laser
9. Penn Treaty Files 2006 Form 10-K
10. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
11. Conseco Files 10-K and Sets Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: